Education Alert
Navigating Advances in TRK Fusion-Positive Cancers: A Collaborative Journey From Testing to Therapy
0.50 CME / ABIM MOC
Are you regularly testing for TRK fusions in cancers with high fusion frequency?


 

Learn how inflammatory mechanisms drive COPD pathophysiology
Education Alert
IL-33 in COPD: The Alarmin Signal Driving Inflammation and Tissue Damage
15 min EBAC
How do different inflammatory pathways contribute to the pathophysiology of COPD, and what is the role of IL???33?
 

Education Alert
Episode 1: The Need for Targeted Biologic Intervention in COPD
15 min EBAC
Get up to date on the complex heterogeneity of chronic obstructive pulmonary disease and the latest therapies available to treat it.

Optimizing First-Line Treatment in EGFR+ mNSCLC: Balancing Efficacy, CNS Control, and Safety
This program provides an in-depth discussion on the evolving treatment strategies for patients with EGFR-mutant metastatic non-small cell lung cancer (mNSCLC), emphasizing the role of combination therapies to improve survival outcomes. Experts review recent clinical trial data, particularly focusing on central nervous system (CNS)-active regimens such as amivantamab plus lazertinib and osimertinib combinations. They highlight patient selection, emphasizing high-risk populations with CNS metastases or high tumor burden, and discuss the clinical rationale for early, aggressive therapy versus de-escalation approaches. Safety, tolerability, and patient-centered care are emphasized, including management of adverse events and considerations for quality of life.

Featured Video
CNS Disease and Intracranial Management in EGFR-Mutant mNSCLC
Experts discuss the efficacy of amivantamab and lazertinib in treating EGFR mutations, highlighting improved outcomes and reduced CNS metastases.

Education Alert
Expert-Driven, Patient-Focused: Mastering Personalized Care for HER2-Low Metastatic Breast Cancer
0.25 CPD
What's really the difference between HER2-negative and HER2-low disease? See how this distinction impacts real treatment decisions.

Updates in Prostate Cancer

FDA Approves Novel Blood-Based Prostate Cancer Test for Elevated PSA Levels

JANX007 Displays Encouraging Safety/Efficacy in Metastatic CRPC

177Lu/SBRT Improves PFS in Oligorecurrent Hormone-Sensitive Prostate Cancer

CLINICAL ADVANCES IN Management of Lung Cancer

Supported by an independent educational grant from F. Hoffman-La Roche Ltd.

New Resources are now available from Medscape Education’s Clinical Advances in The Management of Lung Cancer.

NEW Conference Insights: Breaking Developments in ALK-Positive NSCLC and ES-SCLC
Are you staying up to date on the latest practice-changing data revolutionizing the treatment for lung cancer?

Advances in Lung Cancer Management
Face off against your colleagues in a fast-paced series of medical questions about lung cancer! Deepen knowledge, have fun, and grapple for the number 1 spot on the leaderboard.

Related Resources
Access relevant clinical articles, guidelines, and downloadable slides.

Clinical Advances in The Management of Lung Cancer is a thematic curriculum for physicians, dedicated to improving the management of patients with lung cancer. 

Steering Committee